FreshRecalls

⚠ Data freshness notice: the most recent refresh of NHTSA was incomplete, so a very recent recall may be missing. Everything shown is accurate as of the last checked time on this page — for anything time-critical, confirm with the official sources linked below.

FDAClass II · Drug · Recalled June 10, 2026

Niacin Extended-release Tablets recall — Lannett Company Inc.

Hazard: Failed Dissolution Specifications: during 12M LT stability testing OOS low for Stage 3 dissolution at the 24-hour timepoint.

Class II: may cause temporary or medically reversible health consequences.

View the official FDA enforcement record (openFDA) ↗

Official recall ID
D-0584-2026
Brand
Lannett Company
Classification
Class II
Units affected
3984 bottles
Recall status
Ongoing
Initiated
Voluntary: Firm initiated

Description

Niacin Extended-release Tablets, USP, 1,000 mg, 90-count bottles, Rx Only, Distributed by: Lannett Company, Inc., Philadelphia, PA 19136, NDC 62175-322-46.

Affected products

Companies & origin

Recalling firm location
Seymour, IN, United States
Firm address
1101 C Ave W, 47274-3342

Identifying details (verbatim from the notice)

Product codes / lots
Lot #: 25282724A, Exp. Date 2027/01
Distribution
Nationwide within the United States
Firm notified the public via
Letter
FDA event ID
99107
Recall initiated
May 27, 2026
FDA classified
June 10, 2026
FDA report date
June 10, 2026

Source: U.S. Food & Drug Administration. This page mirrors the official public-domain record verbatim; the linked government source is authoritative. Source last checked July 23, 2026 at 11:04 PM UTC.

Report a data error on this page